Currently the business is focusing on launching their sole product which is classified as (PSD502); it’s a treatment remedy for male premature ejaculation.
Brief history of the company
The company hasn’t always been developing the one drug and back in 2010 it has 11 products in their portfolio with products treating overactive bladder, interstitial cystitis, erectile dysfunction and so forth. The company used to have a subsidiary called the Urology Company Limited which acts for promoting Plethora’s products. On 25 Feb 2013 the company decided to appoint administrators to Urology due to the growing cost of maintaining that business, also it has decided to focus on their main product (PSD 502) having re-purchase the rights from Shionogi for global commercial uses of all markets.
In June 2012 the business has submitted a dossier to the European Medicines Agency for the approval of their product. The CHMP a committee to the EMA has given their approval for human use. By 19th Nov 2013 the European Commission have granted the marketing authorities of the drug.
Having gained the patent it seeks European approval to stop third parties from using the company’s data and market information until Nov 2021 and Nov 2023 respectively. The main strategy is to seek a major partner to help with the sales and marketing of the product in the near future.
Does the company product works?
The company has stated that after 3 months the treatment should help men to last 3 to 4 times longer than any placebo, also it must be spray on the penis for 5 minutes before intercourse become effective. The results of their clinical trials are shown in their website.
So what is PE and the size of market?
According to the International Society of Sexual Medicine (ISSM) characterised this as by: ‘ejaculation that always or nearly always occurs prior to or within about one minute of vaginal penetration; the inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences such as distress, bother, frustration and/or the avoidance of sexual intimacy.’
A study done by the company and verify by various medical websites has found that Europe has 150m men where an estimated of 20% to 30% of men experience (PE) this gives the potential population of 30m-45m.
Competition
The company has research their market and has found that current…
